Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver
disease company developing novel bile acid modulators, today
presented clinical data from its Phase 3 PEDFIC 1 study and an
interim data cut of the PEDFIC 2 long-term extension study of its
lead product candidate, Bylvay (odevixibat). Data being shared at
the 6th World Congress of Pediatric Gastroenterology, Hepatology,
and Nutrition (WCPGHAN) Meeting on June 2 – 5 shows that long-term
treatment (up to 48 weeks) was associated with clinically
meaningful, positive effects on cholestasis, growth, and sleep
parameters in patients with progressive familial intrahepatic
cholestasis (PFIC). The totality of the data supports the potential
of Bylvay to provide benefits to patients with PFIC. Bylvay is a
potent, once-daily, non-systemic ileal bile acid transport
inhibitor (IBATi) currently being developed for the treatment of
PFIC, biliary atresia, and Alagille syndrome.
“The data being presented at WCPGHAN showed consistent long-term
safety and tolerability across studies, treatment groups, and doses
and long-term treatment benefits of Bylvay in children with PFIC,”
said Ron Cooper, President and Chief Executive Officer of Albireo.
“These results not only give us confidence in the potential for
Bylvay in patients with PFIC, but also in our global pivotal
studies in biliary atresia and Alagille syndrome.”
Long-Term Safety and TolerabilityPEDFIC 1 was
the first and largest, global, pivotal Phase 3 study conducted in
PFIC, which evaluated the efficacy and tolerability of Bylvay in
reducing pruritus and serum bile acids in a randomized,
double-blind, placebo-controlled trial, and PEDFIC 2 is a
long-term, open-label Phase 3 extension study. Bylvay improved
pruritus, cholestasis, and growth with durable effect.
The data being presented confirms the safety and tolerability of
Bylvay in children with PFIC. The observed safety and tolerability
profile of Bylvay was consistent across studies, treatment groups,
and doses. The analyses discussed in this oral presentation include
data for of the safety and tolerability of Bylvay in children with
PFIC treated in both PEDFIC 1 and PEDFIC 2 treated for up to 48
weeks. No drug-related serious adverse events were reported in
either PEDFIC 1 or PEDFIC 2. One patient in PEDFIC 1 and 3 patients
in PEDFIC 2 treated with Bylvay withdrew due to an adverse event.
There were low numbers of gastrointestinal adverse events;
specifically, treatment-related diarrhea/frequent bowel movements
was reported in 10% of Bylvay treated patients in PEDFIC 1 and 5%
of placebo-treated patients.
Long-Term Benefits of BylvayThe oral
presentation shows data for secondary and exploratory efficacy
outcomes from the PEDFIC 1 and PEDFIC 2 studies, including growth,
hepatic chemistries, and sleep parameters. The PEDFIC 2 study
observed two cohorts:
Cohort 1 consists of PFIC1 and PFIC2 patients from PEDFIC 1 who
rolled into PEDFIC 2. This includes patients treated with Bylvay,
as well as patients treated with placebo.
Cohort 2 consists of newly enrolled patients who did not
participate in the PEDFIC 1 trial, including patients with PFIC1,
PFIC2, PFIC3 and MYO5B deficiency.
At the PEDFIC 2 interim data cut, median duration of exposure to
Bylvay was 43 weeks in patients treated with Bylvay, 36 weeks for
cohort 1 patients previously treated with placebo in PEDFIC 1, and
19 weeks in cohort 2. Long-term treatment with Bylvay was
associated with clinically meaningful, positive effects on
cholestasis, growth, and sleep parameters in patients with PFIC.
The totality of the data support the potential of Bylvay to provide
benefits to patients with PFIC. Key findings include:
- Significant improvement in height and weight:
Mean height Z scores in the patient group treated with Bylvay
increased significantly from –1.6 to –0.5 (P=0.02) with 48 weeks of
treatment; similarly, those in the treatment naive group
experienced increases in height Z score with 24 weeks of Bylvay.
Changes in weight mirrored those observed with height (e.g., weight
Z scores in patients treated with Bylvay normalized over 48 weeks
[P=0.02; P=0.03]).
- Significant decreases in total bilirubin and serum
ALT: In addition to the previously reported decreases in
pruritus and serum bile acids in PEDFIC 1 and PEDFIC 2, Bylvay also
decreased total bilirubin levels by 20 – 25 µmol/L, further
indicating an improvement of cholestasis.
- Reductions in the percentage of days needing help to
fall asleep, needing soothing, and sleeping with
caregiver: From weeks 24–48 with Bylvay (both groups),
there were reductions in the percentage of days needing help to
fall asleep (P<0.0001 vs P=0.005, respectively), needing
soothing (P<0.0001 vs P=0.12), and sleeping with caregiver
(P=0.001 vs P=0.15).
The long-term data from the PEDFIC 2 study collectively reaffirm
Bylvay’s potential to be the first drug treatment approved for
patients living with PFIC, a devastating disease which is currently
treated with surgical options including liver transplantation.
The abstracts will also be published as an abstract book in the
Journal of Pediatric Gastroenterology and Nutrition (JPGN).
Validation of the PRUCISION Caregiver-Reported
(ObsRO) Pruritus MeasureThe PRUCISION
observer-reported (ObsRO) pruritus measurement tool, which was
developed to adequately measure pruritus in pediatric patients, was
used in the Phase 3 PEDFIC 1 and PEDFIC 2 studies. The data shows
that the PRUCISION ObsRO pruritus measure is reliable, valid, and
sensitive to change, and as such, is appropriate for evaluating the
effect of treatment on pruritus in PFIC and potentially in other
pediatric CLDs. A clinically meaningful ObsRO score change
threshold of −1.00 was established. The PRUCISION ObsRO pruritus
measurement tool is also being used to assess the primary endpoint
in the ongoing phase 3 ASSERT trial for children with Alagille
syndrome.
About Bylvay
(odevixibat)Bylvay is an investigational
product candidate being developed to treat rare pediatric
cholestatic liver diseases, including PFIC, biliary atresia and
ALGS. A potent, once-daily, non-systemic ileal bile acid transport
inhibitor (IBATi), Bylvay acts locally in the small
intestine. Bylvay does not require refrigeration and can be
taken as a capsule for older children, or opened and sprinkled onto
food, which are factors of key importance for adherence in a
pediatric patient population. The FDA has granted Priority Review
and set a PDUFA goal date of July 20, 2021. In Europe, the EMA
validated MAA. Bylvay is the only IBATi granted accelerated
assessment by the EMA.
Bylvay also been granted Orphan Designation, as well as access
to the PRIority MEdicines (PRIME) scheme for the treatment of PFIC.
The EMA’s Pediatric Committee has agreed to Albireo’s Bylvay
Pediatric Investigation Plans for PFIC and biliary atresia. In
addition to PFIC, Bylvay has Orphan Drug Designations for the
treatment of Alagille syndrome, biliary atresia and primary biliary
cholangitis. With FDA and EMA regulatory submissions complete,
Bylvay has the potential to become the first approved drug
treatment for patients with PFIC in the U.S. and Europe. The
Company anticipates potential regulatory approvals, issuance of a
rare pediatric disease priority review voucher and launch in the
second half of 2021.
The MAA and NDA filings are supported by results from PEDFIC 1
and PEDFIC 2 Phase 3 studies. PEDFIC 1 was the first and largest,
global, pivotal Phase 3 study conducted in PFIC, which evaluated
the efficacy and tolerability of Bylvay in reducing pruritus and
serum bile acids in a randomized, double-blind, placebo-controlled
trial. In the PEDFIC 1 study, Bylvay met both primary endpoints and
was well tolerated with very low incidence of diarrhea/frequent
bowel movements (9.5% of Bylvay treated patients vs. 5.0% of
placebo patients).
ir.albireopharma.com/news-releases/news-release-details/albireo-phase-3-trial-meets-both-primary-endpoints-odevixibat.
PEDFIC 2 is a long-term, open-label Phase 3 extension study. The
Company also provides an Expanded Access Program (EAP) for eligible
patients with PFIC in the U.S., Europe, Canada and Australia.
Bylvay is also currently being evaluated in the BOLD Phase 3 trial
in patients with biliary atresia, and the global Phase 3 ASSERT
trial for ALGS.
About AlbireoAlbireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat rare pediatric and adult liver diseases.
Albireo’s lead product candidate, Bylvay, is being developed to
treat rare pediatric cholestatic liver diseases with Phase 3 trials
in PFIC, Alagille syndrome and biliary atresia. For PFIC, the FDA
recently granted Priority Review and set a PDUFA goal date of July
20, 2021. In Europe, the EMA validated MAA. Bylvay is the only
IBATi granted accelerated assessment by the EMA. Bylvay has been
provisionally accepted by both the FDA and EMA as the brand name
for odevixibat. The Company has also initiated a Phase 1 clinical
trial for A3907 to advance development in adult cholestatic liver
disease, with IND-enabling studies moving ahead with A2342 for
viral and cholestatic liver disease. Albireo was spun out from
AstraZeneca in 2008 and is headquartered in Boston, Massachusetts,
with its key operating subsidiary in Gothenburg, Sweden. The Boston
Business Journal named Albireo one of the 2020 Best Places to Work
in Massachusetts for the second consecutive year. For more
information on Albireo, please visit www.albireopharma.com.
Forward-Looking Statements This press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements, other than statements of historical
fact, regarding, among other things: the plans for, or progress,
scope, cost, initiation, duration, enrollment, results or timing
for availability of results of, development of Bylvay or any other
Albireo product candidate or program; expectations regarding the
impact of the COVID-19 pandemic on our business and our ability to
adapt our plans and activities as appropriate; the pivotal trial
for Bylvay in biliary atresia (BOLD), and the pivotal trial for
Bylvay in Alagille syndrome (ASSERT); the target indication(s) for
development or approval, the size, design, population, location,
conduct, cost, objective, enrollment, duration or endpoints of any
clinical trial, or the timing for initiation or completion of or
availability or reporting of results from any clinical trial,
including the long-term open-label extension study for Bylvay in
PFIC, BOLD, ASSERT and the Phase 1 clinical trial for A3907; the
potential approval and commercialization of Bylvay and the timing
for such potential approval and commercialization; the potential
for Bylvay to become the first approved drug for PFIC patients;
discussions with the FDA or EMA regarding our programs; the
potential benefits or competitive position of Bylvay or any other
Albireo product candidate or program or the commercial opportunity
in any target indication; the potential effects of Bylvay of the
treatment of PFIC patients and its potential to improve the current
standard of care; the potential benefits of an orphan drug
designation; the potential issuance of a rare pediatric disease
priority review voucher; or Albireo’s plans, expectations or future
operations, financial position, revenues, costs or expenses.
Albireo often uses words such as “anticipates,” “believes,”
“plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,”
“should,” “could,” “estimates,” “predicts,” “potential,” “planned,”
“continue,” “guidance,” or the negative of these terms or other
similar expressions to identify forward-looking statements. Actual
results, performance or experience may differ materially from those
expressed or implied by any forward-looking statement as a result
of various risks, uncertainties and other factors, including, but
not limited to: whether the NDA for Bylvay for the treatment of
pruritus in patients with PFIC will be approved by the FDA and
whether the MAA for Bylvay in PFIC will be approved by the EMA;
whether the FDA or EMA will complete their respective reviews
within the target timelines, including the FDA’s PDUFA goal date,
as a potential result of the impact of the COVID-19 pandemic or
otherwise; the risk that the NDA will not be approved despite the
FDA’s acceptance of the NDA for review or that the MAA will not be
approved despite CHMP’s opinion recommending approval of Bylvay for
the treatment of PFIC; whether the FDA or EMA will require
additional information, whether we will be able to provide in a
timely manner any additional information that the FDA or EMA
requests, and whether such additional information will be
satisfactory to the FDA and EMA; other potential negative impacts
of the COVID-19 pandemic, including on manufacturing, supply,
conduct or initiation of clinical trials, or other aspects of our
business; whether favorable findings from clinical trials of Bylvay
to date, including findings in indications other than PFIC, will be
predictive of results from other clinical trials of Bylvay; whether
either or both of the FDA and EMA will determine that the primary
endpoint for their respective evaluations and treatment duration of
the double-blind Phase 3 trial in patients with PFIC are sufficient
to support approval of Bylvay in the United States or the European
Union, to treat PFIC, a symptom of PFIC, a specific PFIC subtype(s)
or otherwise; the outcome and interpretation by regulatory
authorities of the ongoing third-party study pooling and analyzing
of long-term PFIC patient data; the timing for initiation or
completion of, or for availability of data from, clinical trials of
Bylvay or A3907, including BOLD and ASSERT, and the outcomes of
such trials; Albireo’s ability to obtain coverage, pricing or
reimbursement for approved products in the United States or
European Union; delays or other challenges in the recruitment of
patients for, or the conduct of, company’s clinical trials; and
Albireo’s critical accounting policies. These and other risks and
uncertainties that Albireo faces are described in greater detail
under the heading “Risk Factors” in Albireo’s most recent Annual
Report on Form 10-K or in subsequent filings that it makes with the
Securities and Exchange Commission. As a result of risks and
uncertainties that Albireo faces, the results or events indicated
by any forward-looking statement may not occur. Albireo cautions
you not to place undue reliance on any forward-looking statement.
In addition, any forward-looking statement in this press release
represents Albireo’s views only as of the date of this press
release and should not be relied upon as representing its views as
of any subsequent date. Albireo disclaims any obligation to update
any forward-looking statement except as required by applicable
law.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLisa Rivero,
617-947-0899, lisa.rivero@syneoshealth.com
Investor Contact:Hans Vitzthum, LifeSci
Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024